AbstractWe evaluated the impact of adding dexamethasone before chemotherapy in 95 children with de novo standard-risk acute lymphoblastic leukemia (ALL). The children were randomly divided into 2 groups: one group was given dexamethasone, the other was not. The initial characteristics and mean follow-up of both groups were similar. Day +14 blast percentage was significantly lower in the dexamethasone group. Disease-free survival at 40-months follow-up was better (almost significantly so) in the dexamethasone group.
Figures & Tables
Vol. 89 No. 3 (2004): March, 2004 : Clinical Trial
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com